Evidence map›Paper›PMID 41864210›Full record

ArticleImmunity2026

Multiomic analysis of ART-interruption cohorts identifies cell-extrinsic and -intrinsic mechanisms driving lymphocyte-mediated control of HIV rebound.

Tongcui Ma, Ashley F George, Zichong Li, Reuben Thomas, Kailin Yin, Min-Gyoung Shin, Mauricio Montano, Yusuke Matsui, Manickam Ashokkumar, Kyrlia Young and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Tongcui MaGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Ashley F GeorgeGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Zichong LiGladstone Institutes, San Francisco, CA 94158, USA.
Reuben ThomasGladstone Institutes, San Francisco, CA 94158, USA.
Kailin YinGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Min-Gyoung ShinGladstone Institutes, San Francisco, CA 94158, USA.
Mauricio MontanoGladstone Institutes, San Francisco, CA 94158, USA.
Yusuke MatsuiGladstone Institutes, San Francisco, CA 94158, USA.
Manickam AshokkumarDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Kyrlia YoungGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Julia PrigannGladstone Institutes, San Francisco, CA 94158, USA.
Julie FrouardGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA.
Sabrina LeddyDepartment of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.
Maisha AdibaLeibniz Institute of Virology, Hamburg, Germany.
Christina HerrdeLeibniz Institute of Virology, Hamburg, Germany.
Ulrike C LangeLeibniz Institute of Virology, Hamburg, Germany; Institute of Infection Research and Vaccine Development, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Cedric FeschotteDepartment of Molecular Biology and Genetics, Cornell University, Ithaca, NY, USA.
Douglas F NixonInstitute of Translational Research, Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA.
Edward P BrowneDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Nancie M ArchinDepartment of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Davey SmithSchool of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.
Steven DeeksUniversity of California, San Francisco, San Francisco, CA 94158, USA.
Ole S SøgaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Martin TolstrupDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Sulggi LeeUniversity of California, San Francisco, San Francisco, CA 94158, USA.
Satish K PillaiUniversity of California, San Francisco, San Francisco, CA 94158, USA; Vitalant Research Institute, San Francisco, CA 94105, USA.
Mohamed Abdel-MohsenDivision of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Center for Human Immunobiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA; Potocsnak Longevity Institute, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.
Katherine S PollardGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA; Biohub, San Francisco, CA 94158, USA.
Robert SilicianoDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Melanie OttGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA; Biohub, San Francisco, CA 94158, USA. Electronic address: melanie.ott@gladstone.ucsf.edu.
Warner C GreeneGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: warner.greene@gladstone.ucsf.edu.
Nadia R RoanGladstone Institutes, San Francisco, CA 94158, USA; University of California, San Francisco, San Francisco, CA 94158, USA. Electronic address: nadia.roan@gladstone.ucsf.edu.

Funding

AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related InfectionsUM1AI068636 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 to 2025
$229.0M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · 2021 to 2025
$81.6M
AIDS Clinical Trial Group Laboratory CenterUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2021 to 2025
$54.5M
San Francisco Bay Clinical Trials Unit (CTU)UM1AI069496 · NIAID · PUBLIC HEALTH FOUNDATION ENTERPRISES · 2021 to 2025
$8.3M
Collaboratory of AIDS Researchers for Eradication (CARE)UM1AI164567 · UNIV OF NORTH CAROLINA CHAPEL HILL · 2025 to 2025
$5.2M
HOPE - HIV Obstruction by Programmed EpigeneticsUM1AI164559 · J. DAVID GLADSTONE INSTITUTES · 2025 to 2025
$5.0M
Estrogen's Impact on IgG Glycomic Modulation of Immunity and Inflammation During HIVR01AI189353 · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · 2025 to 2025
$2.5M
Glycomic Modulation of Gut Microbiome During HIV InfectionR01DK123733 · NIDDK · WISTAR INSTITUTE · PI ALI KESHAVARZIAN, Emmanouil Papasavvas · 2022 to 2024
$2.4M
High-Definition Characterization of the Persistence and Perturbation of the HIV Reservoir: Project 3P01AI169768 · BRIGHAM AND WOMEN'S HOSPITAL · 2025 to 2025
$1.7M
The heterogeneous HIV expressing reservoir: dynamics, persistence mechanisms, tissue distribution, and contribution to reboundP01AI169606 · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2025 to 2025
$1.6M
Targeting the transcriptionally-active reservoir to reduce chronic inflammation in aged people with HIVR01AI183286 · J. DAVID GLADSTONE INSTITUTES · 2025 to 2025
$891k
Role of Factor Acetylation in the Regulation of HIV TranscriptionR37AI083139 · J. DAVID GLADSTONE INSTITUTES · 2025 to 2025
$737k
NIAID NIH HHS P01 AI131374NIAID NIH HHS P01 AI169606NIAID NIH HHS P01 AI169768NIAID NIH HHS R01 AI147777NIAID NIH HHS R01 AI165079NIAID NIH HHS R01 AI183286NIAID NIH HHS R01 AI189353NIAID NIH HHS R21 AI172060NIAID NIH HHS R37 AI083139NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069496NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI164559NIAID NIH HHS UM1 AI164567NIA NIH HHS R01 AG092241NIDDK NIH HHS R01 DK123733NIDDK NIH HHS R01 DK131526
6 · The paper itself

Abstract

Immunological mechanisms regulating HIV rebound after antiretroviral therapy (ART) interruption remain unclear. We examined relationships between host factors, HIV reservoir, and HIV time-to-rebound after analytical treatment interruption (ATI) by characterizing pre-ATI peripheral blood mononuclear cells (PBMCs) from 75 ART-suppressed people with HIV (PWH) using high-parameter methods. Across interventional (CLEAR, TEACH, and REDUC) and non-interventional (A5345) cohorts, delayed rebound was not associated with intact HIV. Cohort-specific immune effectors were associated with delayed rebound. RNA sequencing of CD4

Indexed as

CD4-Positive T-LymphocytesHIV-1HIV InfectionsAnimalsAnti-HIV AgentsCohort StudiesDNA-Binding ProteinsFemaleHumansMaleMetforminTranscription FactorsTreatment InterruptionViral LoadAnti-HIV AgentsDDIT4 protein, humanDNA-Binding ProteinsMetforminTranscription FactorsCD4(+) T cellsHIV persistencemetforminNK cellsT cellszinc finger transcription factor

Identifiers

PMID41864210
PMCPMC13245417

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.